The goal of our study was to compare the performance of HercepTest and PATHWAY anti-HER2 (4B5) by correlating IHC results with silver in situ hybridization (SISH) in adenocarcinoma lung specimens. The gene discussed is ERBB2; the disease is adenocarcinoma.